Inventor
YELESWARAM KRISHNASWAMY
US22 patents
⚠️ This page may combine multiple inventors who share the name “YELESWARAM KRISHNASWAMY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INCYTE CORP
21 patentsUS10166191B2Jan 1, 2019
Sustained-release dosage forms of ruxolitinib
INCYTE CORP32 citations97
US9655854B2May 23, 2017
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP55 citations95
US11219624B2Jan 11, 2022
Topical formulation for a JAK inhibitor
INCYTE CORP10 citations94
US10758543B2Sep 1, 2020
Topical formulation for a JAK inhibitor
INCYTE CORP14 citations94
US11337927B2May 24, 2022
Sustained-release dosage forms of ruxolitinib
INCYTE CORP12 citations93
US10874616B2Dec 29, 2020
Sustained-release dosage forms of ruxolitinib
INCYTE CORP17 citations93
US10869870B2Dec 22, 2020
Topical formulation for a JAK inhibitor
INCYTE CORP10 citations92
US10561616B2Feb 18, 2020
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP15 citations92
US11628162B2Apr 18, 2023
Methods of treating cancer with an FGFR inhibitor
INCYTE CORP7 citations85
US11045421B2Jun 29, 2021
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP11 citations83
US11590136B2Feb 28, 2023
Topical formulation for a JAK inhibitor
INCYTE CORP2 citations73
US11571425B2Feb 7, 2023
Topical formulation for a JAK inhibitor
INCYTE CORP2 citations73
US12564593B2Mar 3, 2026
Topical formulation for a JAK inhibitor
INCYTE CORP0 citations62
US12544381B2Feb 10, 2026
Topical formulation for JAK inhibitor
INCYTE CORP0 citations62
US12150943B2Nov 26, 2024
JAK1 pathway inhibitors for the treatment of gastrointestinal disease
INCYTE CORP0 citations62
US11896717B2Feb 13, 2024
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US11596632B2Mar 7, 2023
JAK1 pathway inhibitors for the treatment of gastrointestinal disease
INCYTE CORP1 citations62
US11576865B2Feb 14, 2023
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US11576864B2Feb 14, 2023
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US12226418B2Feb 18, 2025
Dosing regimen for the treatment of PI3K related disorders
INCYTE CORP0 citations60
US12151026B2Nov 26, 2024
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP0 citations60